Junling L. Zhuang

Beijing, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 104 publications

The 517th case:anhidrosis, orthostatic hypotension, dizziness and fatigue, alternating constipation and diarrhea

The 517th case:anhidrosis, orthostatic hypotension, dizziness and fatigue, alternating constipation and diarrhea

Journal: Zhonghua nei ke za zhi
Published: May 08, 2026

A prospective, phase IV study of ixazomib, pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.

A prospective, phase IV study of ixazomib, pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.

Journal: British journal of haematology
Published: March 27, 2026

Immune-mediated multisystem injury associated with monoclonal gammopathy of clinical significance: a case report.

Immune-mediated multisystem injury associated with monoclonal gammopathy of clinical significance: a case report.

Journal: Frontiers in immunology
Published: March 24, 2026

Comparative Effectiveness of Pomalidomide-Based Regimens in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Analysis in China.

Comparative Effectiveness of Pomalidomide-Based Regimens in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Analysis in China.

Journal: Cancers
Published: February 25, 2026

Case Report: HCV-triggered porphyria cutanea tarda in a patient with SEC23B-mutated congenital dyserythropoietic anemia type II.

Case Report: HCV-triggered porphyria cutanea tarda in a patient with SEC23B-mutated congenital dyserythropoietic anemia type II.

Journal: Frontiers in medicine
Published: February 25, 2026

Selinexor in combination with azacitidine or ruxolitinib in myelodysplastic/myeloproliferative neoplasm overlap syndromes: A multicenter prospective study.

Selinexor in combination with azacitidine or ruxolitinib in myelodysplastic/myeloproliferative neoplasm overlap syndromes: A multicenter prospective study.

Journal: Cancer
Published: December 26, 2025

Value of gene mutation in the prognosis and treatment of multiple myeloma

Value of gene mutation in the prognosis and treatment of multiple myeloma

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: December 17, 2025

Prognostic Value of Next-Generation Flow Cytometry Versus Dual-Tracer PET/CT for Minimal Residual Disease Assessment in Multiple Myeloma.

Prognostic Value of Next-Generation Flow Cytometry Versus Dual-Tracer PET/CT for Minimal Residual Disease Assessment in Multiple Myeloma.

Journal: Cancer medicine
Published: October 17, 2025

Classical complement activation in light and heavy chain deposition disease with acquired cutis laxa and bronchiolitis obliterans: a case report of monoclonal gammopathy of clinical significance.

Classical complement activation in light and heavy chain deposition disease with acquired cutis laxa and bronchiolitis obliterans: a case report of monoclonal gammopathy of clinical significance.

Journal: Frontiers in immunology
Published: October 06, 2025

Quadruplet daratumumab in combination with bortezomib, lenalidomide, and dexamethasone as front-line regimen improved clinical outcomes in high-risk myeloma patients in China: a multi-centered prospective real-world study.

Quadruplet daratumumab in combination with bortezomib, lenalidomide, and dexamethasone as front-line regimen improved clinical outcomes in high-risk myeloma patients in China: a multi-centered prospective real-world study.

Journal: BMC cancer
Published: September 30, 2025

Rapid Recognition of Carfilzomib-Induced Thrombotic Microangiopathy and Early Application of Eculizumab Successfully Rescued Two Relapsed Myeloma Patients.

Rapid Recognition of Carfilzomib-Induced Thrombotic Microangiopathy and Early Application of Eculizumab Successfully Rescued Two Relapsed Myeloma Patients.

Journal: Chronic diseases and translational medicine
Published: September 08, 2025

Effective treatment of refractory aplastic anemia with romiplostim after failure of multiple thrombopoietin receptor agonists: a single-center retrospective study.

Effective treatment of refractory aplastic anemia with romiplostim after failure of multiple thrombopoietin receptor agonists: a single-center retrospective study.

Journal: Annals of medicine
Published: June 19, 2025
Showing 1-12 of 104

Last Updated: 09/26/2026